Afuco™ Anti-Human FZD10 ADCC Recombinant Antibody (OTSA101), ADCC Enhanced (CAT#: AFC-282CL)

Figure 1 Biodistribution of ̶¹¹¹In-OTSA101 and ̶²¹¹At-OTSA101 in the SS subcutaneous xenograft mouse model.

Uptakes (%ID/g) of 111In in the tumor and other organs at 1 h, 3 h, 1 d, 2 d and 4 d after injection of 111In-OTSA101 (A) and 211At at 1 h, 3 h and 1 d after injection of 211At-OTSA101 (B). Five mice were used at each timepoint in both groups. All data represent the mean ± SD

Li,H. K.,Sugyo,A.,Tsuji,A.B.,Morokoshi,Y.,Minegishi,K.,Nagatsu,K.,& Nakamura,Y.(2018).α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10. Cancer science, 109(7), 2302-2309.

Figure 2 Herapeutic results of radioimmunotherapy (RIT) with 211At-OTSA101 and 90Y-OTSA101 in the synovial sarcoma (SS) subcutaneous xenograft mouse model.

Changes in tumor volumes in the model mice after RIT with 211At-OTSA101 (A) and 90Y-OTSA101 (B) are shown. Plots were interrupted if the animal reached the defined endpoint. Kaplan-Meier survival curves of mice after RIT with 211At-OTSA101 (C) and 90Y-OTSA101 (D). Five mice were enrolled in each of the treatment groups, except for the intact IgG control (4 mice). *P < .05, **P < .01, vs intact IgG control

Li,H. K.,Sugyo,A.,Tsuji,A.B.,Morokoshi,Y.,Minegishi,K.,Nagatsu,K.,& Nakamura,Y.(2018).α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10. Cancer science, 109(7), 2302-2309.

Figure 3 The animal body weights to assess the toxicity of both radiolabeled antibodies.

Body weights of the mice after treatment with 211At-OTSA101 (A) or 90Y-OTSA101 (B). Plots were interrupted if the animal reached the defined endpoint. Data represent the mean ± SD

Li,H. K.,Sugyo,A.,Tsuji,A.B.,Morokoshi,Y.,Minegishi,K.,Nagatsu,K.,& Nakamura,Y.(2018).α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10. Cancer science, 109(7), 2302-2309.